These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31181844)

  • 21. Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance.
    Ariston Gabriel AN; Jiao Q; Yvette U; Yang X; Al-Ameri SA; Du L; Wang YS; Wang C
    Pancreatology; 2020 Jan; 20(1):79-88. PubMed ID: 31780287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice.
    Seifert L; Werba G; Tiwari S; Giao Ly NN; Nguy S; Alothman S; Alqunaibit D; Avanzi A; Daley D; Barilla R; Tippens D; Torres-Hernandez A; Hundeyin M; Mani VR; Hajdu C; Pellicciotta I; Oh P; Du K; Miller G
    Gastroenterology; 2016 Jun; 150(7):1659-1672.e5. PubMed ID: 26946344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.
    Knoop RF; Sparn M; Waldmann J; Plassmeier L; Bartsch DK; Lauth M; Hudemann C; Fendrich V
    Neoplasia; 2014 Jun; 16(6):463-70. PubMed ID: 24953430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer.
    Husain K; Centeno BA; Chen DT; Hingorani SR; Sebti SM; Malafa MP
    Cancer Prev Res (Phila); 2013 Oct; 6(10):1074-83. PubMed ID: 23963802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical study.
    de Castro Silva I; Bianchi A; Deshpande NU; Sharma P; Mehra S; Garrido VT; Saigh SJ; England J; Hosein PJ; Kwon D; Merchant NB; Datta J
    Elife; 2022 Sep; 11():. PubMed ID: 36107485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamics of intestinal and intratumoral microbiome signatures in genetically engineered mice and human pancreatic ductal adenocarcinoma.
    Pfisterer N; Ammer-Herrmenau C; Antweiler K; Küffer S; Ellenrieder V; Neesse A
    Pancreatology; 2023 Sep; 23(6):663-673. PubMed ID: 37541802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer.
    Ramu I; Buchholz SM; Patzak MS; Goetze RG; Singh SK; Richards FM; Jodrell DI; Sipos B; Ströbel P; Ellenrieder V; Hessmann E; Neesse A
    EBioMedicine; 2019 Oct; 48():161-168. PubMed ID: 31597597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.
    Mahajan UM; Teller S; Sendler M; Palankar R; van den Brandt C; Schwaiger T; Kühn JP; Ribback S; Glöckl G; Evert M; Weitschies W; Hosten N; Dombrowski F; Delcea M; Weiss FU; Lerch MM; Mayerle J
    Gut; 2016 Nov; 65(11):1838-1849. PubMed ID: 27196585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: A suitable tool for preclinical studies.
    de Latouliere L; Manni I; Iacobini C; Pugliese G; Grazi GL; Perri P; Cappello P; Novelli F; Menini S; Piaggio G
    Ann Anat; 2016 Sep; 207():2-8. PubMed ID: 26704357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.
    Ostapoff KT; Awasthi N; Cenik BK; Hinz S; Dredge K; Schwarz RE; Brekken RA
    Mol Cancer Ther; 2013 Jul; 12(7):1190-201. PubMed ID: 23696215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.
    Torres MP; Rachagani S; Souchek JJ; Mallya K; Johansson SL; Batra SK
    PLoS One; 2013; 8(11):e80580. PubMed ID: 24278292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.
    Lee JW; Komar CA; Bengsch F; Graham K; Beatty GL
    Curr Protoc Pharmacol; 2016 Jun; 73():14.39.1-14.39.20. PubMed ID: 27248578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
    Fendrich V; Sparn M; Lauth M; Knoop R; Plassmeier L; Bartsch DK; Waldmann J
    Pancreatology; 2013; 13(5):502-7. PubMed ID: 24075515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver.
    Grünwald B; Harant V; Schaten S; Frühschütz M; Spallek R; Höchst B; Stutzer K; Berchtold S; Erkan M; Prokopchuk O; Martignoni M; Esposito I; Heikenwalder M; Gupta A; Siveke J; Saftig P; Knolle P; Wohlleber D; Krüger A
    Gastroenterology; 2016 Nov; 151(5):1011-1024.e7. PubMed ID: 27506299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.
    Jiang H; Liu X; Knolhoff BL; Hegde S; Lee KB; Jiang H; Fields RC; Pachter JA; Lim KH; DeNardo DG
    Gut; 2020 Jan; 69(1):122-132. PubMed ID: 31076405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance.
    Ajina R; Malchiodi ZX; Fitzgerald AA; Zuo A; Wang S; Moussa M; Cooper CJ; Shen Y; Johnson QR; Parks JM; Smith JC; Catalfamo M; Fertig EJ; Jablonski SA; Weiner LM
    Cancer Immunol Res; 2021 Apr; 9(4):386-400. PubMed ID: 33509790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo.
    Ye J; Yuen SM; Murphy G; Xie R; Kwok HF
    Eur J Pharm Sci; 2017 Dec; 110():62-69. PubMed ID: 28554668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A ketogenic diet in combination with gemcitabine increases survival in pancreatic cancer KPC mice.
    Cortez NE; Rodriguez Lanzi C; Hong BV; Xu J; Wang F; Chen S; Ramsey JJ; Pontifex MG; Müller M; Vauzour D; Vahmani P; Hwang CI; Matsukuma K; Mackenzie GG
    Cancer Res Commun; 2022 Sep; 2(9):951-965. PubMed ID: 36382086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models.
    Goetze RG; Buchholz SM; Patil S; Petzold G; Ellenrieder V; Hessmann E; Neesse A
    J Vis Exp; 2018 Apr; (134):. PubMed ID: 29683461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.